-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the 2019 ASCO meeting, the latest results of the KEYNOTE-062 study were announced, including 763 patients with locally advanced, HER2-negative, unresectable or metastatic GC/GEJC with PD-L1 CPS ≥ 1, and patients with PD-L1 CPS ≥ 1.
Updated results from the ASCO KEYNOTE-062 study, including 763 patients with locally advanced, HER2-negative, PD-L1 CPS ≥ 1, unresectable or metastatic GC/GEJC, among patients with PD-L1 CPS ≥ 1, pembrolizumab Monoclonal antibody single-agent OS was non-inferior to chemotherapy; in patients with PD-L1 CPS ≥ 10, although pembrolizumab achieved a clinically meaningful OS improvement compared to chemotherapy, its combination with chemotherapy compared Chemotherapy alone was used as first-line treatment for advanced GC/GEJC, and no improvement in progression-free survival (PFS) or OS was observed
Perioperative treatment is the standard of care for the treatment of locally advanced (LA) GC/GEJ adenocarcinoma
This is a multicenter, single-arm, phase II clinical trial of pembrolizumab 200 mg every 3 weeks combined with capecitabine 625 mg/m2 twice daily and Thaliplatin 130 mg/m2 every 3 weeks (CAPOX)
Between February 10, 2017, and June 17, 2021, 36 patients were enrolled, of whom 34 (21 gastric, 13 GEJ) were eligible for efficacy evaluation
At the time of data cutoff, the median follow-up time was 19 months
The 1- and 2-year survival rates were 91% (0.
In conclusion, in LA GC/GEJ adenocarcinoma, the combination of CAPOX and pembrolizumab resulted in a pCR rate of 20.
6%
.
The combination was well tolerated, with 85.
3% of patients undergoing surgical resection
.
The trial met its primary endpoint, supporting further study of this regimen as an alternative in patients who are unlikely to tolerate triple chemotherapy
.
leave a message here